21
The group is formed by Reithera, based in the metropolitan region of Rome, Leukocare, in Munich (Germany), and Univercells, in Charleroi (Belgium). “Currently, Reithera is carrying out preparatory activities to start phase 1 and 2 clinical trials in Italy during the summer of 2020”, says a note from the consortium
Read more in ISTOÉ
